echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Preliminary safety results of the introduction phase of the 2022 SOHO| Phase III LOTIS-5 trial: Lonca combined with rituximab for the treatment of R/R DLLBCL

    Preliminary safety results of the introduction phase of the 2022 SOHO| Phase III LOTIS-5 trial: Lonca combined with rituximab for the treatment of R/R DLLBCL

    • Last Update: 2022-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com




    Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) usually do not respond well
    with standard therapy.
    Loncastuximab tesirine(Loncastuximab tesirine-lpyl; Lonca) is a novel antibody drug conjugate (ADC) consisting of pyrrolobenzobenzodiazepine (PBD) dimer cytoxin conjugated with an anti-CD19 monoclonal antibody for patients with R/R DLBCL after prior treatment with ≥
    2-line systems.
    Whether as first-line or follow-up therapy, rituximab (R) is part of standard immunotherapy for
    DLBCL.
    There is preclinical evidence that the addition of rituximab to targeted CD19 ADC therapy may prolong tumor control time
    .
    Based on this, the investigators conducted the LOTIS-5 trial to evaluate the efficacy of standard immunotherapy of Lonca+R (Lonca-R) and R+ gemcitabine + oxaliplatin (R-GemOx) in patients with R/R DLBC, and at this year's annual meeting of the American Society of Hematology-Oncology (SOHO), the investigators announced the safety and preliminary efficacy results
    of Lonca-R.



    01Research methods


    The study was a phase III, randomized, open-label, two-part, two-arm, multicenter study
    .
    Part 1 is a non-randomized safety lead-in period in which 20 patients are enrolled to determine the safety of
    Lonca-R.
    In Part 2, approximately 330 patients will be randomized to receive either Lonca-R or R-GemOx in a 1:1 ratio
    .
    The key inclusion criteria were: (1) age≥ 18 years; (2) Patients diagnosed with DLBCL (including DLBCL converted from indolent lymphoma) or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement; (3) Have received ≥ first-line systemic therapy in the past; (4) Do not meet the conditions for hematopoietic stem cell transplantation; (5) Diseases
    that can be evaluated according to Lugano 2014 criteria.
    The study protocol is detailed in Figure 1
    .


    Figure 1


    The primary endpoint was progression-free survival (PFS).

    Secondary endpoints were overall survival (OS), overall response rate (ORR), safety, duration of response (DOR), pharmacokinetics, and change in
    patient-reported outcomes.


    02Research results


    The median age of the 20 patients in the safety transition period was 74.
    5 years (range 35-93 years), and the median number of previous treatments was 1 (range 1-6).

    The baseline characteristics of the patient are shown
    in Table 1.


    Table 1


    As of 28 February 2022, the median number of doses was 5 (range: 1-8) and the median follow-up was 5.
    83 months (range: 1.
    9-10.
    3).


    Nineteen (95%) patients developed ≥ 1 adverse event (TEAE) during treatment, and 10 (50%) patients developed grade 3 TEAE
    ≥.
    The most common of all grades of TEAE were rash (5 [25%]), fatigue (4 [20%]), and elevated γ-glutamyltransferase (4 [20%]).

    The most common grade 3 TEAE ≥ were elevated γ-glutamyltransferase (3 [15%]), elevated alanine aminotransferase (2 [10%]), and neutropenia (2 [10%]).

    The patient's ORR was 15/20 (75%)
    .
    A total of 8/20 (40%) and 7/20 (35%) achieved a complete and partial response
    , respectively.
    The efficacy and safety are shown
    in Table 2.


    Table 2


    03Research conclusion


    Lonca-R showed no new safety signals in patients with R/R DLBCL in the safety lead-in phase and had good antitumor activity
    .


    Reference sources

    Kingsley E,et al.
    Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/ R DLBCL.
    2022 SOHO.
    ABCL-320.


    Editor: moly Review: Quinta Typesetting: moly Execution: moly



    Poke "Read Original" to see more

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.